Tactical Therapeutics Selected To Present At Cavendish Global Health Impact Forum

NEW YORK--(BUSINESS WIRE)--Tactical Therapeutics, Inc., a clinical stage oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10^th to May 14^th in La Jolla, California. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. http://cavendishglobal.com

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to treat and manage newly diagnosed and recurrent glioblastoma and other malignant gliomas afflicting populations around the world today”

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our La Jolla, California Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ The quality and originality of Tactical Therapeutics’ research and scientific insights in glioblastoma positions them to make a major contribution to the treatment and management of this orphan indication, glioblastoma, for which there is an unmet need because of lack of effective treatments.”

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to treat and manage newly diagnosed and recurrent glioblastoma and other malignant gliomas afflicting populations around the world today,” said Rashida Karmali, Ph.D, CEO at Tactical Therapeutics. “We welcome the chance to interact with many of world’s most accomplished individuals and families who are all dedicated to improving the health and lives of people around the world.”

About Tactical Therapeutics, Inc.: Tactical Therapeutics, Inc. is a clinical stage company that has developed and patented a lead therapeutic, Carboxyamidotriazole Orotate (CTO), for the orphan indication glioblastoma (GBM) and malignant glioma. CTO is a novel oral inhibitor of calcium signal transduction signaling pathways active in glioblastoma. CTO is currently in multiple Phase I/II trials for GBM with several leading cancer research institutions, including Memorial Sloan-Kettering Cancer Center, Duke Cancer Center, and New York University Brain Tumor Center. In Phase I studies on recurrent GBM, CTO given orally in combination with Temodar® showed a very safe toxicity profile. Durable stable disease and partial responses are confirmed in both methylated and unmethylated MGMT GBM tumors. Studies in newly diagnosed GBM are underway. Given encouraging clinical signals of activity, CTO randomized trials are warranted. Tactical Therapeutics is seeking strategic partners. www.tacticaltherapeutics.com